Clinical trial
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00059475 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00059475 |
|---|---|
| Title | Peptide Vaccination for Patients at High Risk for Recurrent Melanoma |
| Official title | Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51, Melanoma antigen recognized by T-cells (MART)-1: 27-35, 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1, melanoma antigen recognized by T-cells (MART)-1: 26-35(27L) |
| Enrollment | 138 |
| Start date | Apr 1, 2003 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Apr 28, 2003 |
| Last update posted | Oct 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: